--- title: Two Ebola Treatments Show Promise, CDC Says description: Two therapies, the antiviral remdesivir and antibodies included in ZMapp, could work as treatments for Ebola in the Congo, the CDC says. canonical: https://time.com/5623496/ebola-treatments-cdc/ author: Jamie Ducharme article:opinion: false article:content_tier: free article:published_time: 2019-07-10T16:13:37.000Z article:modified_time: 2026-02-23T23:57:02.526Z article:section: Health og:title: Two Therapies Show Promise for Treating Ebola, CDC Says og:description: An experimental vaccine also seems effective og:url: https://time.com/5623496/ebola-treatments-cdc/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt840223dcc49830d4/6989ffc98fd2ee350e35fc40/ebola-congo.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 og:image:width: 1024 og:image:height: 576 og:image:alt: Medical staff dressed in protective gear before entering an og:type: article twitter:card: summary_large_image twitter:title: Two Therapies Show Promise for Treating Ebola, CDC Says twitter:description: An experimental vaccine also seems effective twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt840223dcc49830d4/6989ffc98fd2ee350e35fc40/ebola-congo.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 ---  # Experimental Ebola Treatments Look Successful in Lab Studies, Says the CDC > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=41acebc5-55a5-4ad7-b897-b4619d7fc02b&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=41acebc5-55a5-4ad7-b897-b4619d7fc02b&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=41acebc5-55a5-4ad7-b897-b4619d7fc02b&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=41acebc5-55a5-4ad7-b897-b4619d7fc02b&cr=time-nl-network-2026q3-v1)  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Jul 10, 2019 4:13 PM UTC  Medical staff dressed in protective gear before entering an isolation area at an Ebola treatment centre in Goma. Medical staff dressed in protective gear before entering an isolation area at an Ebola treatment centre in Goma. SOPA Images—LightRocket via Getty Images  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Jul 10, 2019 4:13 PM UTC A humanitarian crisis, attacks on health workers and[ rampant misinformation](https://time.com/5609718/rumors-spread-ebola-drc/) have for months fueled[ an Ebola outbreak](https://time.com/5606544/ebola-outbreak-drc-uganda/) in the Democratic Republic of the Congo (DRC), amplifying the effects of a highly contagious and often-fatal disease. As a result, international health groups have declared this the second-worst Ebola outbreak in history, with more than 1,500 people dying since it started in August 2018. New research from the U.S. Centers for Disease Control and Prevention (CDC) offers some hope, highlighting two treatments that could help bring the[ deadly outbreak under control](https://time.com/5609838/ebola-outbreak-drc/). [The study](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2819%2930291-9/fulltext#seccestitle170), published in _the Lancet Infectious Diseases_, finds that two experimental Ebola treatments—Gilead Sciences’ antiviral drug remdesivir, and antibodies included in a Mapp Biopharmaceutical cocktail known as ZMapp—were shown in a lab to slow the viral strain found in the DRC, potentially offering an effective treatment to those who become infected with the hemorrhagic fever. There is no known cure for Ebola. There are some treatments available, but all were “developed to fight Ebola viruses from previous outbreaks,” lead study author and CDC microbiologist Laura McMullan said in a statement. “It’s vitally important to make sure existing treatments work against the virus that’s making people sick now.” CDC researchers isolated and recreated the specific viral strain circulating in the DRC, which is known as the Ituri strain, and studied its activity in human cells in a secure laboratory. This allowed them to compare the Ituri strain to past forms of Ebola, and to test treatments with a high degree of specificity. They also confirmed that diagnostic tests currently in use in the DRC can accurately detect Ebola. While remdesivir and ZMapp could offer relief to those who are already sick with Ebola, a vaccine made by Merck is also showing promise at preventing transmission in the first place. Merck’s vaccine is still experimental and has not yet been approved by government agencies, but it has been used in the DRC under “compassionate use” rules, which allow drugs under investigation to be used in the absence of other options. [World Health Organization data](https://www.who.int/csr/resources/publications/ebola/ebola-ring-vaccination-results-12-april-2019.pdf?ua=1) suggest the vaccine has about a 97.5% efficacy rate.[ A 2016 trial conducted in Guinea](https://time.com/4611239/ebola-vaccine-infection-virus/), one of the countries ravaged by Ebola during a West African outbreak that killed more than 11,000 people from 2014 to 2016, also suggested the vaccine could effectively prevent infection. The DRC outbreak has yet to reach that scale, but its continuing intensity and recent[ presence in neighboring Uganda](https://time.com/5610731/ebola-outbreak-congo-uganda/)—and the sociopolitical challenges that have hampered response efforts—have health officials worried. The CDC says its results “support the continued testing of remdesivir and ZMapp in DR Congo,” which could, at least, offer some help. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/5623496/ebola-treatments-cdc/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/5623496/ebola-treatments-cdc/"},"headline":"Experimental Ebola Treatments Look Successful in Lab Studies, Says the CDC","datePublished":"2019-07-10T16:13:37.000Z","dateModified":"2026-02-23T23:57:02.526Z","description":"An experimental vaccine also shows promise","url":"https://time.com/5623496/ebola-treatments-cdc/","keywords":["Infectious Disease"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt840223dcc49830d4/6989ffc98fd2ee350e35fc40/ebola-congo.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Jamie Ducharme","jobTitle":"Ducharme is a contributor to TIME.","url":"https://time.com/author/jamie-ducharme/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt840223dcc49830d4/6989ffc98fd2ee350e35fc40/ebola-congo.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Medical staff dressed in protective gear before entering an","caption":"Medical staff dressed in protective gear before entering an","creditText":"SOPA Images—LightRocket via Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/tag/infectious-disease/","name":"Infectious Disease"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/5623496/ebola-treatments-cdc/","name":"Experimental Ebola Treatments Look Successful in Lab Studies, Says the CDC"}}]}] ```